Exelixis files patent infringement suit against Cipla over generic CABOMETYX

EXELIXIS, INC.

Filed complaint in Delaware district court against Cipla for ANDA seeking approval of generic cabozantinib tablets (20/40/60 mg).
Five patents asserted: U.S. Patents Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 11,298,349, with latest expiry Feb. 10, 2032.
Exelixis seeks injunction and order delaying any FDA approval until after patent expirations; Cipla did not challenge compound patent expiring Aug. 14, 2026.
CABOMETYX is a key revenue driver for Exelixis; generic entry could impact sales if patents are invalidated or not infringed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.